Head and neck cancer is the sixth most common form of malignancy world-wide. Surgery, chemotherapy and radiation are typically associated with at least seven weeks of treatment and a high burden of side effects. Tumour recurrence within the primary site or the neck continues to be the most common cause of treatment failure. There remains a need for therapeutic strategies which can improve loco-regional control and provide symptom relief while limiting treatment duration and side effects. This clinical pilot study will utilize magnetic resonance guided focused ultrasound to treat cancer of the head and neck, prior to standard palliative radiotherapy andd/or chemotherapy treatments. If proven safe and technically feasible, MRFUS for head and neck cancer has the potential to drastically decrease side effects and treatment time while improving tumour cure rates. Future applications could include focused ultrasound alone, in combination with current treatments or as a mechanism for precise drug delivery.